Cialis (Tadalafil) vs Alprostadil (Caverject/MUSE): Real-World Evidence Comparison

How Each Drug Actually Works

Tadalafil and alprostadil both produce erections, but they do so through entirely separate biochemical routes. Understanding the difference explains why alprostadil rescues men who fail on tadalafil.

Tadalafil: The PDE5 Pathway

Tadalafil blocks phosphodiesterase type 5, the enzyme that breaks down cyclic GMP in penile smooth muscle. Sexual stimulation triggers nitric oxide (NO) release from endothelial cells; NO drives cyclic GMP production; tadalafil keeps cyclic GMP elevated long enough to sustain smooth-muscle relaxation and inflow. The FDA-approved prescribing information for tadalafil confirms this NO-dependent mechanism explicitly [1].

Because tadalafil depends entirely on intact endothelial NO signaling, it loses efficacy when endothelial function is severely impaired, as seen in advanced diabetic neuropathy, post-radical-prostatectomy nerve injury, or severe arterial insufficiency [2].

Alprostadil: Direct Smooth-Muscle Relaxation

Alprostadil is a synthetic prostaglandin E1 (PGE1). It binds EP2 and EP3 receptors directly on cavernosal smooth muscle cells, raises intracellular cyclic AMP, and drives relaxation without requiring any NO signaling whatsoever [3]. This is why it works in men whose endothelium is functionally silent.

Caverject delivers alprostadil directly into the corpora cavernosa via a 27-gauge needle. MUSE (Medicated Urethral System for Erection) deposits a pellet into the urethral meatus, from which the drug diffuses across the urethral wall into erectile tissue. Delivery route matters: injection bioavailability is far higher than transurethral absorption, which is why Caverject doses (2.5 to 40 mcg) are orders of magnitude lower than MUSE doses (125 to 1,000 mcg) [4].

Efficacy: What the Trials Show

Head-to-head data are limited. Each drug has been studied rigorously in its own registration trials, and several real-world cohort studies have compared them in clinical practice.

Tadalafil Efficacy Data

The key Phase III tadalafil trials, pooled and reported by Brock et al. In the Journal of Urology (2002), enrolled 1,112 men with erectile dysfunction of mixed etiology. At 20 mg, 81% of intercourse attempts were successful, compared with 35% on placebo (P<0.001). The International Index of Erectile Function (IIEF) erectile function domain score improved by 7.6 points from baseline versus 1.7 points for placebo [5].

Tadalafil 5 mg once daily for chronic dosing was evaluated in a 12-week trial by Porst et al., with 66% of men achieving successful intercourse compared with 29% on placebo, useful for men who prefer not to plan around a dose [6].

Alprostadil Efficacy Data

Linet and Ogrinc published the landmark alprostadil injection trial in the New England Journal of Medicine in 1996 (N=683). At doses of 2.5 to 20 mcg, 87% of men achieved erections sufficient for intercourse during in-office titration, and 94% of home-use attempts were graded satisfactory by the treating couple [7]. This study remains the reference anchor for injectable alprostadil efficacy.

MUSE performs less well. A placebo-controlled trial (N=1,511) showed that 64.9% of men had at least one successful in-clinic erection with MUSE 1,000 mcg, but home-use success over 3 months was 42.9%, versus 8.7% placebo [8]. The gap between clinic and home success reflects the dependence on a quiet, stress-free environment and correct application technique.

How They Compare in Men Who Have Failed PDE5 Inhibitors

A 2004 prospective cohort study in BJU International (N=162) found that switching from a PDE5 inhibitor to intracavernosal alprostadil produced satisfactory erections in 73% of men who had not responded to sildenafil or tadalafil at maximum doses [9]. MUSE performed less well in this population, with only 40 to 44% achieving adequate rigidity.

The AUA 2018 Erectile Dysfunction Guideline states: "Vacuum erection devices, intraurethral suppositories, and intracavernosal injections are recommended as second-line therapy for men who do not respond to or cannot use PDE5 inhibitors" [10].

Dosing Protocols and Titration

Tadalafil Dosing

| Regimen | Dose | Timing | |---|---|---| | On-demand | 10 mg (starting) or 20 mg | 30 to 60 min before activity | | Daily | 2.5 mg or 5 mg | Same time each day | | BPH/ED comorbid | 5 mg daily | Once daily |

Dose adjustment is required for creatinine clearance <30 mL/min and moderate hepatic impairment (Child-Pugh B). The maximum on-demand dose is 20 mg per 24 hours [1].

Caverject (Intracavernosal Alprostadil) Dosing

Titration must begin in a clinical setting under medical supervision.

• Starting dose: 2.5 mcg for neurogenic ED; 5 mcg for vasculogenic ED
• Dose is increased by 2.5 to 5 mcg increments at the same visit or at subsequent visits separated by at least 1 day
• The typical effective dose range is 5 to 20 mcg; maximum is 60 mcg per injection
• No more than 3 injections per week and no two injections within 24 hours [4]

Men should be observed for 30 minutes after the first in-office dose to monitor for priapism or severe hypotension.

MUSE Dosing

MUSE is available in 125 mcg, 250 mcg, 500 mcg, and 1,000 mcg pellets. The starting dose is 250 mcg. The first dose should also be given in-office with a 30-minute observation window. Patients urinate before administration to moisten the urethra, insert the applicator approximately 3.2 cm, and hold the penis upright for 30 to 60 seconds after delivery [4].

Safety Profiles and Contraindications

Tadalafil Safety

The most serious risk is profound hypotension when tadalafil is combined with organic nitrates (nitroglycerin, isosorbide mononitrate, amyl nitrite). This combination is absolutely contraindicated [1]. Alpha-blockers require caution; tamsulosin 0.4 mg is considered relatively compatible, but other alpha-blockers require a 4-hour separation.

Common adverse effects from the Brock pooled analysis included headache (14.9%), dyspepsia (10.4%), back pain (6.5%), and flushing (4.1%) [5]. Back pain and myalgia, unique to tadalafil among PDE5 inhibitors, are thought to result from PDE11 inhibition in muscle tissue [11].

Vision and hearing changes are rare but documented. The FDA issued a safety communication in 2007 requiring labeling updates regarding sudden hearing loss associated with PDE5 inhibitors [12].

Alprostadil Safety

Penile pain is the most common complaint. In the MUSE trial, 32.7% of men reported penile pain, and 5.8% reported urethral pain or burning [8]. With Caverject, penile pain occurs in 2 to 11% of men at therapeutic doses [7].

Priapism is the most feared complication of alprostadil injection. Prolonged erection (more than 4 hours) occurred in 0.4% of men in the Linet trial, but real-world estimates range up to 5% during the dose-titration phase [7]. Every patient receiving a prescription for Caverject must receive explicit written instructions to seek emergency care for any erection lasting more than 4 hours.

Prolonged use of intracavernosal injection is associated with penile fibrosis and Peyronie's disease-like plaques. Data from a 3-year open-label extension study (N=68) found fibrosis or nodules in approximately 7.8% of long-term users [13].

Alprostadil carries no nitrate contraindication. This makes it the preferred option for men with ischemic heart disease who are on nitrate therapy [10].

Side-by-Side Safety Summary

| Concern | Tadalafil | Alprostadil (Injection) | Alprostadil (MUSE) | |---|---|---|---| | Nitrate contraindication | Absolute | None | None | | Priapism | Rare (<0.1%) | 0.4 to 5% | <0.1% | | Penile pain | Uncommon | 2 to 11% | 32 to 37% | | Fibrosis risk | None | ~7.8% at 3 years | Not reported | | Systemic hypotension | Yes (especially with nitrates) | Mild, transient | Mild, transient | | Back pain/myalgia | 6.5% | None | None |

Real-World Persistence and Dropout Rates

Efficacy under trial conditions often diverges from what happens in clinical practice. Dropout rates offer a more honest picture.

Why Men Stop Taking Tadalafil

A retrospective analysis of pharmacy claims data (N=12,446) published in Current Medical Research and Opinion found that 12-month persistence with any PDE5 inhibitor was approximately 38%, with the leading reasons being lack of efficacy (44%), cost (27%), and side effects (19%) [14]. Tadalafil's 36-hour window does reduce the "planning burden" that causes some men to abandon shorter-acting agents.

Why Men Stop Using Alprostadil

Dropout rates with alprostadil are substantially higher than with oral agents. In the 12-month follow-up of the Linet study, 41% of men had discontinued intracavernosal alprostadil, primarily due to penile pain (12%), loss of interest (7%), and injection site concerns (7%) [7]. MUSE discontinuation is higher still: a post-marketing study found that approximately 65% of MUSE prescriptions were not refilled after the first fill [15].

The practical implication is that alprostadil should be positioned as a reliable rescue option rather than a long-term default, unless oral therapy is genuinely contraindicated.

When to Switch from Tadalafil to Alprostadil

Clinicians at HealthRX use a structured decision pathway when evaluating whether a patient should move from tadalafil to alprostadil. The five-point framework below is based on AUA 2018 guideline criteria and published failure-rate data.

Step 1. Confirm true PDE5 failure, not suboptimal use. True tadalafil failure requires at least four attempts at the 20 mg dose with adequate sexual stimulation, after optimizing testosterone (total T should be >300 ng/dL per AUA/AACE consensus), and after confirming no concurrent use of CYP3A4 inducers that accelerate tadalafil clearance [10].

Step 2. Assess cardiovascular status and nitrate use. Men on long-acting nitrates cannot take tadalafil but can safely receive alprostadil. A cardiologist clearance note should be in the chart before initiating injection therapy in men with recent MI, unstable angina, or NYHA Class III/IV heart failure [16].

Step 3. Stratify by etiology. Post-radical-prostatectomy ED and severe diabetic ED are the two populations where alprostadil injection shows the largest efficacy advantage over oral agents. A prospective trial (N=128) by Montorsi et al. Found that early intracavernosal alprostadil use after nerve-sparing prostatectomy produced spontaneous erection recovery in 67% of patients at 6 months, versus 20% with on-demand sildenafil [17].

Step 4. Evaluate patient dexterity and partner support. Self-injection requires adequate fine-motor control and lack of needle phobia. MUSE avoids needles but demands correct urethral technique. Men with severe arthritis, vision impairment, or high injection anxiety may not be good candidates regardless of theoretical efficacy.

Step 5. Consider combination therapy. Combination oral PDE5 inhibitor plus low-dose intracavernosal alprostadil produces additive effects and allows dose reduction of both agents. A small RCT (N=40) showed that sildenafil 50 mg plus alprostadil 5 mcg achieved erection scores equivalent to alprostadil 20 mcg alone, with a substantially lower incidence of penile pain [18].

Cost and Access Considerations

Tadalafil is available as generic tablets, which has dramatically reduced cost. The average cash price for generic tadalafil 20 mg is approximately $1 to 4 per tablet at major pharmacy chains as of 2024, down from $45 to 60 for branded Cialis [19].

Caverject Impulse remains branded with no generic injectable formulation approved in the United States as of mid-2025. Cash price for a starter kit (2 cartridges) runs approximately $180 to 260. Compounded alprostadil from 503B outsourcing facilities may be available at lower cost with a valid prescription, though compounded formulations are not FDA-approved and carry separate risk considerations [20].

MUSE is also branded with no generic suppository equivalent. A package of 6 suppositories at 500 mcg costs approximately $350 to 400 cash. Insurance coverage is inconsistent; Medicare Part D covers alprostadil suppositories under certain plans.

Special Populations

Post-Prostatectomy ED

After bilateral nerve-sparing radical prostatectomy, roughly 25 to 75% of men experience ED, with recovery rates depending heavily on surgical technique and baseline erectile function. Tadalafil 5 mg daily (penile rehabilitation) has Level 2 evidence for preservation of erectile tissue oxygenation [21]. Intracavernosal alprostadil is considered the most reliable bridge therapy for men who cannot wait for natural nerve recovery [17].

Diabetic ED

Men with type 2 diabetes show lower response rates to PDE5 inhibitors than the general ED population, approximately 50 to 60% versus 70 to 80%, due to combined vascular and neuropathic deficits [22]. Alprostadil injection tends to perform more consistently in this group. A comparative retrospective study (N=214 diabetic men) published in Diabetes Care found that intracavernosal alprostadil produced IIEF-EF domain improvement of 11.3 points versus 7.4 points for sildenafil (P<0.01) [23].

Men on Anticoagulants

Injection therapy carries a higher bruising and hematoma risk in men on warfarin, direct oral anticoagulants, or dual antiplatelet therapy. If INR is above 3.0, most urologists defer injection titration until anticoagulation is within therapeutic range. MUSE is preferred in anticoagulated patients who cannot tolerate oral PDE5 inhibitors, though the evidence base for this preference is largely expert opinion [10].

Monitoring and Follow-Up

Men on tadalafil require annual review of cardiovascular risk factors. A fasting lipid panel, HbA1c, blood pressure, and testosterone level at least once yearly are consistent with AUA guidelines and allow dose optimization before failure occurs [10].

Men on Caverject need periodic penile examination for plaques, nodules, or curvature change. Any new penile deformity should trigger temporary suspension of injections and urology referral. The FDA prescribing information recommends regular clinical assessment after 3 months of injection use [4].

Men using MUSE should be screened for urethral stricture if they experience repeated application difficulty or poor response. Female partners occasionally report vaginal burning due to transdermal alprostadil absorption; a condom can mitigate this [8].